Drugs / Alintegimod
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04508179 | Oct 2020 → Oct 2021 | cancer | 7 Hills Pharma, LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06362369 | Aug 2024 → Dec 2027 expected | cancer of unknown primary site, colorectal cancer, hepatocellular carcinoma, melanoma +5 | 7 Hills Pharma, LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2022-05-18 | 7 Hills Pharma, LLC | Results New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors 7hillspharma.com ↗ |
| 2022-05-12 | 7 Hills Pharma, LLC | Results LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade 7hillspharma.com ↗
Here, we show that 7HP349, a small-molecule activator of lymphocyte function–associated antigen-1 (LFA-1) and very late activation antigen-4 (VLA-4) integrin cell-adhesion receptors, facilitated the preferential localization of tumor-specific T cells to the tumor and improved antitumor response. |
| 2022-03-08 | 7 Hills Pharma, LLC | Regulatory 7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma 7hillspharma.com ↗ |
| 2021-11-01 | 7 Hills Pharma, LLC | Results 7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19, and Influenza Vaccines 7hillspharma.com ↗
No treatment-related adverse events were observed throughout the Single Ascending Dose and Multiple Ascending Dose portions of the study at exposures exceeding 9x therapeutic levels. |
| 2021-09-08 | 7 Hills Pharma, LLC | Results Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease 7hillspharma.com ↗
When delivered systemically in a model of Chagas disease following immunization with a DNA subunit vaccine encoding candidate T. cruzi antigens, TcG2 and TcG4, 7HP349 enhanced the vaccine efficacy in both prophylactic and therapeutic settings. |
| 2020-07-07 | 7 Hills Pharma, LLC | Results 7 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines 7hillspharma.com ↗
7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, announced today that preclinical studies reveal 7HP349, an oral integrin activator that promotes cell adhesion, significantly increases IgG binding antibodies with a vaccine targeting SARS-CoV-2 (COV2), the virus that causes COVID-19. |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alintegimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06362369 ↗ |
| Known as | 7HP349 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04508179 ↗ |
| Action | Activate | “an allosteric integrin activator” NCT04508179 ↗ |
| Modality | Small molecule | — CHEMBL5314453 ↗ |
| Route | Oral | “following single and multiple oral dose administration” NCT04508179 ↗ |